Next Article in Journal
Nano Delivers Big: Designing Molecular Missiles for Cancer Therapeutics
Next Article in Special Issue
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults
Previous Article in Journal
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats
Previous Article in Special Issue
Pediatric Dosing and Body Size in Biotherapeutics

The Pharmacokinetics and Pharmacodynamics of Iron Preparations

Research & Development Department, Vifor Pharma – Vifor International Inc, Rechenstrasse 37, St Gallen, CH-9001, Switzerland
Author to whom correspondence should be addressed.
Pharmaceutics 2011, 3(1), 12-33;
Received: 7 December 2010 / Accepted: 27 December 2010 / Published: 4 January 2011
Standard approaches are not appropriate when assessing pharmacokinetics of iron supplements due to the ubiquity of endogenous iron, its compartmentalized sites of action, and the complexity of the iron metabolism. The primary site of action of iron is the erythrocyte, and, in contrast to conventional drugs, no drug-receptor interaction takes place. Notably, the process of erythropoiesis, i.e., formation of new erythrocytes, takes 3−4 weeks. Accordingly, serum iron concentration and area under the curve (AUC) are clinically irrelevant for assessing iron utilization. Iron can be administered intravenously in the form of polynuclear iron(III)-hydroxide complexes with carbohydrate ligands or orally as iron(II) (ferrous) salts or iron(III) (ferric) complexes. Several approaches have been employed to study the pharmacodynamics of iron after oral administration. Quantification of iron uptake from radiolabeled preparations by the whole body or the erythrocytes is optimal, but alternatively total iron transfer can be calculated based on known elimination rates and the intrinsic reactivity of individual preparations. Degradation kinetics, and thus the safety, of parenteral iron preparations are directly related to the molecular weight and the stability of the complex. High oral iron doses or rapid release of iron from intravenous iron preparations can saturate the iron transport system, resulting in oxidative stress with adverse clinical and subclinical consequences. Appropriate pharmacokinetics and pharmacodynamics analyses will greatly assist our understanding of the likely contribution of novel preparations to the management of anemia. View Full-Text
Keywords: iron; pharmacokinetics; pharmacodynamics; iron complex; metabolism; elimination; kinetics; efficacy; safety iron; pharmacokinetics; pharmacodynamics; iron complex; metabolism; elimination; kinetics; efficacy; safety
Show Figures

MDPI and ACS Style

Geisser, P.; Burckhardt, S. The Pharmacokinetics and Pharmacodynamics of Iron Preparations. Pharmaceutics 2011, 3, 12-33.

AMA Style

Geisser P, Burckhardt S. The Pharmacokinetics and Pharmacodynamics of Iron Preparations. Pharmaceutics. 2011; 3(1):12-33.

Chicago/Turabian Style

Geisser, Peter, and Susanna Burckhardt. 2011. "The Pharmacokinetics and Pharmacodynamics of Iron Preparations" Pharmaceutics 3, no. 1: 12-33.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop